<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kozela E</submitter><funding>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</funding><funding>NINDS NIH HHS</funding><funding>NINDS Informatics Center for Neurogenetics and Neurogenomics</funding><pagination>136</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4891926</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Our previous studies showed that the non-psychoactive cannabinoid, cannabidiol (CBD), ameliorates the clinical symptoms in mouse myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune encephalomyelitis model of multiple sclerosis (MS) as well as decreases the memory MOG35-55-specific T cell (TMOG) proliferation and cytokine secretion including IL-17, a key autoimmune factor. The mechanisms of these activities are currently poorly understood.&lt;h4>Methods&lt;/h4>Herein, using microarray-based gene expression profiling, we describe gene networks and intracellular pathways involved in CBD-induced suppression of these activated memory TMOG cells. Encephalitogenic TMOG cells were stimulated with MOG35-55 in the presence of spleen-derived antigen presenting </pubmed_abstract><journal>Journal of neuroinflammation</journal><pubmed_title>Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.</pubmed_title><pmcid>PMC4891926</pmcid><funding_grant_id>P30 NS062691</funding_grant_id><pubmed_authors>Juknat A</pubmed_authors><pubmed_authors>Vogel Z</pubmed_authors><pubmed_authors>Kozela E</pubmed_authors><pubmed_authors>Kaushansky N</pubmed_authors><pubmed_authors>Gao F</pubmed_authors><pubmed_authors>Coppola G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.</name><description>&lt;h4>Background&lt;/h4>Our previous studies showed that the non-psychoactive cannabinoid, cannabidiol (CBD), ameliorates the clinical symptoms in mouse myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune encephalomyelitis model of multiple sclerosis (MS) as well as decreases the memory MOG35-55-specific T cell (TMOG) proliferation and cytokine secretion including IL-17, a key autoimmune factor. The mechanisms of these activities are currently poorly understood.&lt;h4>Methods&lt;/h4>Herein, using microarray-based gene expression profiling, we describe gene networks and intracellular pathways involved in CBD-induced suppression of these activated memory TMOG cells. Encephalitogenic TMOG cells were stimulated with MOG35-55 in the presence of spleen-derived antigen presenting </description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Jun</publication><modification>2026-06-14T09:51:41.965Z</modification><creation>2019-03-27T02:15:15Z</creation></dates><accession>S-EPMC4891926</accession><cross_references><pubmed>27256343</pubmed><doi>10.1186/s12974-016-0603-x</doi></cross_references></HashMap>